April 14, 2026
BUSINESSWIRE
Media
Scroll to learn more
News & Press Releases
JAN 9, 2026
BUSINESSWIRE
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
View ArticleJanuary 5, 2026
EIN Presswire
KeifeRx to Present at Sachs Neuroscience Forum and Biotech Showcase During J.P. Morgan Healthcare Conference Week
View ArticleJune 25, 2025
EIN Presswire
Journal of Clinical Medicine Publishes Results of Phase 2 Trial of Nilotinib in Treatment of Dementia with Lewy Bodies
View ArticleJune 10, 2025
Nov 01, 2024
Practical Neurology
Leukemia Drug Safe and Effective as Treatment for Dementia with Lewy Bodies
View ArticleNov 09, 2024
Daily Mail
Daily tablet shows staggering success in slowing or even reversing dementia in new trials
View ArticleMAR 27, 2024
BUSINESSWIRE
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
View ArticleJAN 8, 2024
PR NEWSWIRE
KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors
View ArticleFEB 14, 2023
JAN 26, 2023
KeifeRx In The Media
JANUARY 1, 2024
LIFE SCIENCE LEADER
KeifeRx has a full range of neuroscience (NS) drug candidates in development, spanning later-stage clinical assets to several novel, pre-IND technologies
View ArticleJul 5, 2023
EMPOWERED PATIENT PODCAST
Using TKIs to Remove Toxic Proteins in the Brain with Chris Hoyt KeifeRx TRANSCRIPT
View ArticleJANUARY 26, 2022
FOX BUSINESS
Keiferx CEO on new method for treating Alzheimer’s, neurodegenerative disease
View ArticleJANUARY 19, 2022